VAXCYTE, INC. Proceeds from Sale of Debt Securities, Available-for-sale
VAXCYTE, INC. (PCVX) reported Proceeds from Sale of Debt Securities, Available-for-sale of $47.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-06-30 was $22.51M, a 46.50% decline year-over-year.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-03-31 was $24.88M, a 4.54% decline year-over-year.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $68.22M, a 178.15% increase year-over-year.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $38.33M, a 44.64% increase year-over-year.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $174.69M, a 160.89% increase from fiscal 2024.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $66.96M, a 432.01% increase from fiscal 2023.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $12.59M, a 13.08% decline from fiscal 2022.
- VAXCYTE, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $14.48M, a 51.83% decline from fiscal 2021.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $47.39M 10-Q · filed 2026-08-05 | $115.61M derived: sum of 3 quarters · filed 2026-08-05 | $153.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $24.88M 10-Q · filed 2026-05-06 | $93.11M derived: sum of 2 quarters · filed 2026-05-06 | $131.44M derived: sum of 3 quarters · filed 2026-05-06 | $173.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $68.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $106.55M derived: sum of 2 quarters · filed 2026-02-24 | $148.63M derived: sum of 3 quarters · filed 2026-08-05 | $174.69M 10-K · filed 2026-02-24 |
| 2025-09-30 | $38.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $80.40M derived: sum of 2 quarters · filed 2026-08-05 | $106.47M 10-Q · filed 2025-11-04 | $130.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $42.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $68.14M 10-Q · filed 2026-08-05 | $92.66M derived: sum of 3 quarters · filed 2026-08-05 | $119.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $26.07M 10-Q · filed 2026-05-06 | $50.59M derived: sum of 2 quarters · filed 2026-05-06 | $77.09M derived: sum of 3 quarters · filed 2026-05-06 | $86.65M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $24.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.03M derived: sum of 2 quarters · filed 2026-02-24 | $60.58M derived: sum of 3 quarters · filed 2026-02-24 | $66.96M 10-K · filed 2026-02-24 |
| 2024-09-30 | $26.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $36.05M derived: sum of 2 quarters · filed 2025-11-04 | $42.43M 10-Q · filed 2025-11-04 | $46.23M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $9.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $15.93M 10-Q · filed 2025-08-06 | $19.73M derived: sum of 3 quarters · filed 2026-02-24 | $26.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $6.38M 10-Q · filed 2025-05-07 | $10.17M derived: sum of 2 quarters · filed 2026-02-24 | $16.55M derived: sum of 3 quarters · filed 2026-02-24 | $17.84M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.17M derived: sum of 2 quarters · filed 2026-02-24 | $11.46M derived: sum of 3 quarters · filed 2026-02-24 | $12.59M 10-K · filed 2026-02-24 |
| 2023-09-30 | $6.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.66M derived: sum of 2 quarters · filed 2024-11-05 | $8.79M 10-Q · filed 2024-11-05 | $12.77M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.42M 10-Q · filed 2024-08-06 | $6.40M derived: sum of 3 quarters · filed 2025-02-25 | $13.40M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.13M 10-Q · filed 2024-05-08 | $5.11M derived: sum of 2 quarters · filed 2025-02-25 | $12.11M derived: sum of 3 quarters · filed 2025-02-25 | $15.61M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $10.98M derived: sum of 2 quarters · filed 2025-02-25 | $14.48M derived: sum of 3 quarters · filed 2025-02-25 | $14.48M 10-K · filed 2025-02-25 |
| 2022-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $10.50M derived: sum of 2 quarters · filed 2023-11-06 | $10.50M 10-Q · filed 2023-11-06 | $10.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.50M 10-Q · filed 2023-08-08 | $3.50M derived: sum of 3 quarters · filed 2024-02-27 | $16.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $13.00M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $13.00M derived: sum of 2 quarters · filed 2024-02-27 | $30.06M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $30.06M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $17.06M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |